EUCTR2016-003616-13-DE进行中（未招募）1 期
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Turning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb company)0 个研究点目标入组 630 人开始时间: 2019年10月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 630
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1 or NTRK1-3 gene fusion. Note: Locally advanced disease is defined as Stage III when subject is not a candidate for surgery, radiation, or multi-modality therapy and metastatic disease is defined as Stage IV per the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual guidelines (Rami-Porta 2017).
- •-Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing using either:-
- •a)a next-generation sequencing (NGS) or quantitative polymerase chain
- •reaction (qPCR) test will be accepted to determine molecular eligibility.
- •b)a fluorescence in situ hybridization (FISH) test AND prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility.
- •-At least 1 measurable target lesion according to RECIST (Version 1.1) prospectively confirmed by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to enrollment. Subjects with CNS-only measurable disease =10 mm as defined by RECIST (Version 1.1) are eligible.
- •-Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3 rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all inclusion and exclusion criteria are met: EXP-1: ROS1 TKI-naïve ROS1+ NSCLC (n=110).
- •No prior exposure to a ROS1 TKI is allowed.
- •Up to one prior line of chemotherapy OR immunotherapy is allowed (chemo- or immunotherapy-based combination regimen is considered as one line of treatment).
- •EXP-2: 1 Prior ROS1 TKI and 1 Platinum-based Chemotherapy ROS1+NSCLC (n=120).
- •Disease progression, or intolerant to one prior line of a ROS1 TKI.
- •ROS1 TKIs used in a prior line of treatment are limited to crizotinib, ceritinib, entrectinib, orlorlatinib. Note: Any previous exposure to a ROS1 TKI is considered as one prior line of TKI treatment (e.g., if the same ROS1 TKI was given before and after a chemotherapy or other systemic therapy, it is considered as 2 prior TKIs and the subject would not be eligible for EXP-2).
- •In addition, the subject must have received one prior line of platinum based
- •chemotherapy OR one prior line of platinum-based chemotherapy in combination with immunotherapy before or after a ROS1 TKI (Note: subject is not eligible if he/she has been treated with more than one line of chemotherapy OR has received immunotherapy alone).
- •EXP-3: 2 Prior ROS1 TKIs and NO hemotherapy or Immunotherapy ROS1+ NSCLC (n=80).
- •Disease progression, or intolerant to 2 prior lines of a ROS1 TKI treatment.
- •ROS1 TKIs used in prior lines of treatment are limited to crizotinib, ceritinib, entrectinib, lorlatinib, brigatinib, ensartinib, or cabozantinib.
- •Other prior ROS1 TKI agents that are not listed may be allowed after discussion with the Sponsor Medical Monitor. Note: Any previous exposure to a ROS1 TKI is considered as one prior line of TKI treatment (e.g., if 2 different ROS1 TKIs are utilized, or the same ROS1 TKI was given before and after a chemotherapy or other systemic therapy, it is considered as 2 prior TKIs and the subject would be eligible).
- •No prior lines of chemotherapy or immunotherapy are allowed.
- •EXP-4: 1 Prior ROS1 TKI and NO Chemotherapy or Immunotherapy
- •ROS1+ NSCLC (n=120).
- •Disease progression or intolerant to one prior line of a ROS1 TKI.
排除标准
- •1. Concurrent participation in another therapeutic clinical trial.
- •2. Symptomatic brain metastases or leptomeningeal involvement.
- •3. History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years.
- •4. Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (=10 fractions) must have been completed at least 48 hours prior to study entry.
- •5. Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class = II), cerebrovascular accident or transient ischemic attack, symptomatic
- •bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of CTCAE grade =2.
- •6. Any of the following cardiac criteria:
- •Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) > 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value
- •Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec)
- •Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval
- •7. Known active infections requiring ongoing treatment (bacterial, fungal, viral including human immunodeficiency virus positivity).
- •8. Gastrointestinal disease (e.g., Crohn’s disease, ulcerative colitis, short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.
- •9. Peripheral neuropathy, paresthesia, dizziness, dysgeusia, muscle weakness, ataxia grade =2.
- •10. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior radiation pneumonitis are not excluded.
- •11. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study, or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
- •12. Current use or anticipated need for drugs that are known to be strong CYP3A inhibitors or inducers as listed in Appendix 5 of the protocol.
- •13. Hypersensitivity to the active substance or to any of the excipients.
研究者
相似试验
进行中（未招募）
1 期
Phase 1/2 Open Label solid tumour Safety and Tolerability study.advanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003616-13-BETurning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb company)630
招募中
2 期
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)Advanced solid Tumors harboring ALK, ROS1 or NTRK1-3 rearrangementsAdvanced solid tumors. CancerNL-OMON54586Turning Point Therapeutics (a wholly owned subsidiary of Bristol Myers Squibb company)23
进行中（未招募）
1 期
Phase 1/2 Open Label solid tumour Safety and Tolerability study.advanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2016-003616-13-GBTurning Point Therapeutics, Inc.320
进行中（未招募）
1 期
Phase 1/2 Open Label solid tumour Safety and Tolerability study.advanced solid tumorsMedDRA version: 21.1 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2016-003616-13-ESTurning Point Therapeutics, Inc.320
招募中
1 期
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsPatients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsJPRN-jRCT2011210009Minal Mehta, MBBS20